| Name | Title | Contact Details |
|---|
Oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. Morphic Tx is joining a three decade quest led by our scientific founder, Tim Springer, who initially discovered the integrin receptor family in the 1980s. This receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, Crohn`s disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention.
ChinaPeptides Co.,Ltd is a Louisville, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ON TARGET LABORATORIES discovers and develops fluorescent markers to target and illuminate cancer during surgery so it can be removed more completely.
ALX Oncology is a clinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
TransMolecular, Inc. is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.